Actively Recruiting
Survival Outcomes of EGFR-TKI Drugs in Uncommon EGFR Mutant Advanced Non-Small Cell Lung Cancer
Led by Hunan Province Tumor Hospital · Updated on 2025-01-27
800
Participants Needed
1
Research Sites
404 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the survival outcomes of using EGFR-TKI treatments in patients with uncommon EGFR mutant advanced non-small cell lung cancer (NSCLC) in China. This study focuses on patients with specific EGFR mutations such as G719X and exon 20 insert mutations who have not previously received anti-cancer treatment. The goal is to understand how these targeted therapies perform in this particular group of lung cancer patients. The study involves treatment with EGFR-TKIs, which include third-generation drugs like Osimertinib, Furmonertinib, and Almonertinib, among others. These drugs are given to participants to assess their effectiveness and survival impact. The study may include multiple types of EGFR-TKIs to compare outcomes and gather comprehensive data. Participants will be closely monitored over a period of five years to measure progression-free survival (PFS). Throughout the study, researchers will collect detailed health information and track how the cancer responds to treatment. Safety and effectiveness will be evaluated regularly to better understand the benefits and risks of EGFR-TKI therapy in this patient population.
CONDITIONS
Official Title
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Diagnosis of advanced non-squamous non-small cell lung cancer confirmed by histopathology
- Presence of uncommon EGFR mutations including G719X or exon 20 insert mutation
- No prior anti-cancer treatment for lung cancer
You will not qualify if you...
- Contraindication to chemotherapy
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yongchang Zhang
Changsha, Hunan, China, 410013
Actively Recruiting
Research Team
Y
Yongchang Zhang, MD
N
Nong Yang, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
7
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here